Samsung Bioepis launches U.S. sales of Remicade biosmiliar

SEOUL (Reuters) - South Korea's Samsung Bioepis Co Ltd said it started U.S sales of its copy of Johnson & Johnson's rheumatoid arthritis drug Remicade on Monday - a move set to further undermine sales of the U.S. firm's top-selling drug.